New trial
First-in-Human Study: TYRA-430 in FGFR-Driven Advanced Cancers
- Trial ID
- NCT06915753 on ClinicalTrials.gov
- Cancer type
- Solid Tumors
- Location
- 2 Locations
- Published in
- New in Oncology - May 14, 2025
Tyra Biosciences, Inc. is evaluating TYRA-430—a novel FGFR4 inhibitor—as monotherapy in a dose-escalation and expansion study in patients with advanced hepatocellular carcinoma and other solid tumors harboring activating FGF/FGFR pathway aberrations.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings